In mice, PD-1 blockade reverses glucose restriction in TILs, enhancing CD8+ T cells glucose influx and glycolysis via mTOR signaling, which allows IFN-γ production, improving their effector anti-tumor function [66]. This evidence concerns the gene CD8A and neoplasm.